Tokai Investor Marks Underwriters Liable In $10.8M Suit

By Lauren Berg (November 20, 2018, 6:47 PM EST) -- A Tokai Pharmaceuticals Inc. investor is fighting to keep alive a $10.8 million suit alleging that the company failed to disclose that too few research subjects were left to yield meaningful results in testing of a prostate cancer drug, arguing that the underwriters are liable for misstatements in Tokai investment documents.

Peter Angelos said in an opposition to a motion to dismiss his amended complaint that the underwriters — BMO Capital Markets Corp., Stifel Nicolaus & Company Inc., William Blair & Company LLC and Janney Montgomery Scott LLC — are responsible for failing to disclose to investors that a stage-three test...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!